Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy
Identifieur interne : 008B04 ( Main/Merge ); précédent : 008B03; suivant : 008B05Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy
Auteurs : Pauline T. Truong ; Ivo A. Olivotto ; Timothy J. Whelan ; Mark LevineSource :
- CMAJ : Canadian Medical Association Journal [ 0820-3946 ] ; 2004.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Radiothérapie.
- radiothérapie : Tumeurs du sein.
- Association thérapeutique, Femelle, Humains, Mastectomie, Médecine factuelle, Radiothérapie, Tumeurs du sein.
English descriptors
- KwdEn :
- MESH :
- adverse effects : Radiotherapy.
- methods : Radiotherapy.
- radiotherapy : Breast Neoplasms.
- surgery : Breast Neoplasms.
- Combined Modality Therapy, Evidence-Based Medicine, Female, Humans, Mastectomy.
Abstract
To provide information and recommendations to assist women with breast cancer and their physicians in making decisions regarding the use of locoregional post-mastectomy radiotherapy (PMRT).
Locoregional control, disease-free survival, overall survival and treatment-related toxicities.
This guideline is based on a review of all meta-analyses, consensus statements and other guidelines published between 1966 and November 2002. Searches of MEDLINE and CANCERLIT for English-language randomized controlled trials published between 1995 and November 2002 were also conducted to supplement the literature previously reviewed by the American Society of Clinical Oncology (ASCO) Health Services Research Committee panel in its published guideline. A nonsystematic review of the literature was continued through June 2003.
Locoregional PMRT is recommended for women with an advanced primary tumour (tumour size 5 cm or greater, or tumour invasion of the skin, pectoral muscle or chest wall). Locoregional PMRT is recommended for women with 4 or more positive axillary lymph nodes. The role of PMRT in women with 1 to 3 positive axillary lymph nodes is unclear. These women should be offered the opportunity to participate in clinical trials of PMRT. Locoregional PMRT is generally not recommended for women who have tumours that are less than 5 cm in diameter and who have negative axillary nodes. Other patient, tumour and treatment characteristics, including age, histologic grade, lymphovascular invasion, hormone receptor status, number of axillary nodes removed, axillary extracapsular extension and surgical margin status, may affect locoregional control, but their use in specifying additional indications for PMRT is currently unclear. PMRT should encompass the chest wall and the supraclavicular, infraclavicular and axillary apical lymph node areas. To reduce the risk of lymphedema, radiation of the entire axilla should not be used routinely after complete axillary dissection of level I and II lymph nodes. A definite recommendation regarding the inclusion of the internal mammary lymph nodes in PMRT cannot be made because of limited and inconsistent data. The use of modern techniques in radiotherapy planning is recommended to minimize excessive normal tissue exposure, particularly to the cardiac and pulmonary structures. Common short-term side effects of PMRT, including fatigue and skin erythema, are generally tolerable and not dose-limiting. Severe long-term side effects, including lymphedema, cardiac and pulmonary toxicities, brachial plexopathy, rib fractures and secondary neoplasms, are relatively rare. The optimal sequencing of PMRT and systemic therapy is currently unclear. Regimens containing anthracyclines or taxanes should not be administered concurrently with radiotherapy because of the potential for increased toxicity.
The authors' original text was submitted for review, revision and approval by the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Subsequently, feedback was provided by 11 oncologists from across Canada. The final document was approved by the steering committee.
The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer was convened by Health Canada.
November 2003.
Url:
DOI: 10.1503/cmaj.1031000
PubMed: 15078851
PubMed Central: 385392
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001C54
- to stream Pmc, to step Curation: 001C53
- to stream Pmc, to step Checkpoint: 003E50
- to stream PubMed, to step Corpus: 004028
- to stream PubMed, to step Curation: 004028
- to stream PubMed, to step Checkpoint: 004028
- to stream Ncbi, to step Merge: 001963
- to stream Ncbi, to step Curation: 001963
- to stream Ncbi, to step Checkpoint: 001963
Links to Exploration step
PMC:385392Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy</title>
<author><name sortKey="Truong, Pauline T" sort="Truong, Pauline T" uniqKey="Truong P" first="Pauline T." last="Truong">Pauline T. Truong</name>
</author>
<author><name sortKey="Olivotto, Ivo A" sort="Olivotto, Ivo A" uniqKey="Olivotto I" first="Ivo A." last="Olivotto">Ivo A. Olivotto</name>
</author>
<author><name sortKey="Whelan, Timothy J" sort="Whelan, Timothy J" uniqKey="Whelan T" first="Timothy J." last="Whelan">Timothy J. Whelan</name>
</author>
<author><name sortKey="Levine, Mark" sort="Levine, Mark" uniqKey="Levine M" first="Mark" last="Levine">Mark Levine</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">15078851</idno>
<idno type="pmc">385392</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC385392</idno>
<idno type="RBID">PMC:385392</idno>
<idno type="doi">10.1503/cmaj.1031000</idno>
<date when="2004">2004</date>
<idno type="wicri:Area/Pmc/Corpus">001C54</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001C54</idno>
<idno type="wicri:Area/Pmc/Curation">001C53</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001C53</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003E50</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003E50</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">004028</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004028</idno>
<idno type="wicri:Area/PubMed/Curation">004028</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004028</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004028</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004028</idno>
<idno type="wicri:Area/Ncbi/Merge">001963</idno>
<idno type="wicri:Area/Ncbi/Curation">001963</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001963</idno>
<idno type="wicri:doubleKey">0820-3946:2004:Truong P:clinical:practice:guidelines</idno>
<idno type="wicri:Area/Main/Merge">008B04</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy</title>
<author><name sortKey="Truong, Pauline T" sort="Truong, Pauline T" uniqKey="Truong P" first="Pauline T." last="Truong">Pauline T. Truong</name>
</author>
<author><name sortKey="Olivotto, Ivo A" sort="Olivotto, Ivo A" uniqKey="Olivotto I" first="Ivo A." last="Olivotto">Ivo A. Olivotto</name>
</author>
<author><name sortKey="Whelan, Timothy J" sort="Whelan, Timothy J" uniqKey="Whelan T" first="Timothy J." last="Whelan">Timothy J. Whelan</name>
</author>
<author><name sortKey="Levine, Mark" sort="Levine, Mark" uniqKey="Levine M" first="Mark" last="Levine">Mark Levine</name>
</author>
</analytic>
<series><title level="j">CMAJ : Canadian Medical Association Journal</title>
<idno type="ISSN">0820-3946</idno>
<idno type="eISSN">1488-2329</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast Neoplasms (radiotherapy)</term>
<term>Breast Neoplasms (surgery)</term>
<term>Combined Modality Therapy</term>
<term>Evidence-Based Medicine</term>
<term>Female</term>
<term>Humans</term>
<term>Mastectomy</term>
<term>Radiotherapy (adverse effects)</term>
<term>Radiotherapy (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Association thérapeutique</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mastectomie</term>
<term>Médecine factuelle</term>
<term>Radiothérapie ()</term>
<term>Radiothérapie (effets indésirables)</term>
<term>Tumeurs du sein ()</term>
<term>Tumeurs du sein (radiothérapie)</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Radiothérapie</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term>
<term>Evidence-Based Medicine</term>
<term>Female</term>
<term>Humans</term>
<term>Mastectomy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association thérapeutique</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mastectomie</term>
<term>Médecine factuelle</term>
<term>Radiothérapie</term>
<term>Tumeurs du sein</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Objective</title>
<p>To provide information and recommendations to assist women with breast cancer and their physicians in making decisions regarding the use of locoregional post-mastectomy radiotherapy (PMRT).</p>
</sec>
<sec><title>Outcomes</title>
<p>Locoregional control, disease-free survival, overall survival and treatment-related toxicities.</p>
</sec>
<sec><title>Evidence</title>
<p>This guideline is based on a review of all meta-analyses, consensus statements and other guidelines published between 1966 and November 2002. Searches of MEDLINE and CANCERLIT for English-language randomized controlled trials published between 1995 and November 2002 were also conducted to supplement the literature previously reviewed by the American Society of Clinical Oncology (ASCO) Health Services Research Committee panel in its published guideline. A nonsystematic review of the literature was continued through June 2003.</p>
</sec>
<sec><title></title>
<p><list list-type="bullet"><title>Recommendations</title>
<list-item><p>Locoregional PMRT is recommended for women with an advanced primary tumour (tumour size 5 cm or greater, or tumour invasion of the skin, pectoral muscle or chest wall).</p>
</list-item>
<list-item><p>Locoregional PMRT is recommended for women with 4 or more positive axillary lymph nodes.</p>
</list-item>
<list-item><p>The role of PMRT in women with 1 to 3 positive axillary lymph nodes is unclear. These women should be offered the opportunity to participate in clinical trials of PMRT.</p>
</list-item>
<list-item><p>Locoregional PMRT is generally not recommended for women who have tumours that are less than 5 cm in diameter and who have negative axillary nodes.</p>
</list-item>
<list-item><p>Other patient, tumour and treatment characteristics, including age, histologic grade, lymphovascular invasion, hormone receptor status, number of axillary nodes removed, axillary extracapsular extension and surgical margin status, may affect locoregional control, but their use in specifying additional indications for PMRT is currently unclear.</p>
</list-item>
<list-item><p>PMRT should encompass the chest wall and the supraclavicular, infraclavicular and axillary apical lymph node areas.</p>
</list-item>
<list-item><p>To reduce the risk of lymphedema, radiation of the entire axilla should not be used routinely after complete axillary dissection of level I and II lymph nodes.</p>
</list-item>
<list-item><p>A definite recommendation regarding the inclusion of the internal mammary lymph nodes in PMRT cannot be made because of limited and inconsistent data.</p>
</list-item>
<list-item><p>The use of modern techniques in radiotherapy planning is recommended to minimize excessive normal tissue exposure, particularly to the cardiac and pulmonary structures.</p>
</list-item>
<list-item><p>Common short-term side effects of PMRT, including fatigue and skin erythema, are generally tolerable and not dose-limiting. Severe long-term side effects, including lymphedema, cardiac and pulmonary toxicities, brachial plexopathy, rib fractures and secondary neoplasms, are relatively rare.</p>
</list-item>
<list-item><p>The optimal sequencing of PMRT and systemic therapy is currently unclear. Regimens containing anthracyclines or taxanes should not be administered concurrently with radiotherapy because of the potential for increased toxicity.</p>
</list-item>
</list>
</p>
</sec>
<sec><title>Validation</title>
<p>The authors' original text was submitted for review, revision and approval by the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Subsequently, feedback was provided by 11 oncologists from across Canada. The final document was approved by the steering committee.</p>
</sec>
<sec><title>Sponsor</title>
<p>The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer was convened by Health Canada.</p>
</sec>
<sec><title>Completion date</title>
<p>November 2003.</p>
</sec>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008B04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 008B04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Merge |type= RBID |clé= PMC:385392 |texte= Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:15078851" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |